Monday, March 17, 2025 | 08:08 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

AstraZeneca inks $6.9-bn breast, gastric cancer therapy deal with Daiichi

AstraZeneca said the transaction won't impact earnings this year but will make a 'significant contribution' by 2023

Initiate suitable prosecution steps against AstraZeneca management, pleads FMRI
Premium

Lisa Du and Jeff Sutherland | Bloomberg
AstraZeneca Plc agreed to pay up to $6.9 billion for a piece of a promising cancer treatment in its biggest deal in over a decade as it aims to become a global oncology powerhouse.

AstraZeneca will pay the Japanese drugmaker Daiichi Sankyo Co. $1.35 billion upfront to jointly develop and commercialize the cancer therapy trastuzumab deruxtecan, with as much as $5.6 billion in additional payments subject to sales milestones and other contingencies, the companies said late Thursday. They will also equally split development and commercialization costs.

The Cambridge, U.K.-based company said it will fund the transaction partly through a share

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in